Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc.

Biotechnology • Healthcare • Boston, MA, United States • AVIR (NMS)

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

857 284 8891 225 Franklin Street, Boston, MA 02110, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026 - Seeking Alpha
Seeking Alpha • Dec 23
Atea Pharmaceuticals Completes Enrollment in C-BEYOND Phase 3 Trial for HCV Treatment, Anticipates Topline Results in Mid-2026 - Quiver Quantitative
Quiver Quantitative • Dec 22
Atea (Nasdaq: AVIR) says HCV Phase 3 on track; C-BEYOND topline results mid-2026 - Stock Titan
Stock Titan • Nov 12
Atea Pharmaceuticals Insiders Placed Bullish Bets Worth US$5.40m - Yahoo Finance
Yahoo Finance • Jul 23
Atea Pharmaceuticals (AVIR): Assessing Valuation After C-BEYOND Phase 3 Enrollment Milestone and 2026 Data Timeline - simplywall.st
simplywall.st • Dec 26

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Atea Pharmaceuticals, Inc. had layoffs?
No layoff events have been recorded for Atea Pharmaceuticals, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Atea Pharmaceuticals, Inc. have?
Atea Pharmaceuticals, Inc. has approximately 56 employees.
What industry is Atea Pharmaceuticals, Inc. in?
Atea Pharmaceuticals, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Atea Pharmaceuticals, Inc. a publicly traded company?
Yes, Atea Pharmaceuticals, Inc. is publicly traded under the ticker symbol AVIR on the NMS. The company has a market capitalization of approximately $0.29 billion.
Where is Atea Pharmaceuticals, Inc. headquartered?
Atea Pharmaceuticals, Inc. is headquartered in Boston, MA, United States at 225 Franklin Street, Boston, MA 02110, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.